SeaStar Medical Holding Corporation (ICU) is a Denver-based, commercial-stage medical device company developing the Selective Cytopheretic Device (SCD), a platform therapy that filters blood to calm overactive immune cells and reduce the hyperinflammation that can damage vital organs. Its lead product, QUELIMMUNE, is approved for critically ill children with acute kidney injury (AKI) caused by sepsis. The central question for investors is whether this small-cap name can climb to a $8.00 price objective widely cited in public market discussion.
ICU does not have the breadth of sell-side coverage typical of larger healthcare companies, so there is no reliable multi-analyst average to draw on. Instead, the $8.00 figure reflects the one active, named analyst price target: Maxim Group's Anthony Vendetti raised his target to $8.00 from $6.00 on May 14, 2026, maintaining a Buy rating after first-quarter revenue, gross margin, and loss per share came in above his estimates. Earlier in 2026, the same target had been lowered to $6.00 from $10.00 specifically to reflect share dilution. Because this is a lone, named price objective rather than an analyst consensus, it should be read as one firm's valuation view of the commercial rollout and pipeline, not as a street-wide forecast.
The stock most recently closed near $4.69 (October 2, 2026), with after-hours and pre-market trades around $4.90 to $4.95 as of early October 2026. The 52-week range spans roughly $2.07 to $7.35. Moving from about $4.69 to $8.00 would require an increase of approximately 70%, which is a very large move for any security and especially demanding for a micro-cap with a market value near $20 million. The path would depend heavily on continued commercial execution in the pediatric market, progress toward full enrollment of the NEUTRALIZE-AKI adult trial, and the company's ability to fund operations without excessive additional dilution.
Revenue is growing quickly from a small base: full-year 2025 revenue reached about $1.23 million, up from roughly $135,000 in 2024, and trailing twelve-month revenue stands near $1.71 million. Gross margin has been reported above 95%, reflecting a high-value device business. In the first quarter of 2026, the company added seven new QUELIMMUNE customers among top-tier children's hospitals, bringing its total to 17, and management has guided toward roughly $2 million in net product revenue for 2026. The adult opportunity is considerably larger, and the NEUTRALIZE-AKI pivotal trial had enrolled 198 of 339 patients as of mid-2026, with full enrollment targeted by the end of 2026. The SCD has also received FDA (Food and Drug Administration) Breakthrough Device Designation for six indications, which could support faster development and future commercialization.
The company is not yet profitable, reporting a trailing twelve-month net loss of roughly $13.6 million, with total cash near $7 million. Continued cash burn may require further equity raises, and dilution is a material concern: shares outstanding have increased more than fourfold in a year, which is precisely the factor Maxim cited when it previously cut its target. ICU remains a single-product story, with revenue concentrated in QUELIMMUNE, and adult commercialization depends on successful trial results and regulatory clearance that are not guaranteed. As a micro-cap with a negative beta and elevated volatility, the shares can swing sharply on limited news flow, and an RSI (relative strength index) reading near 77 after a rapid rally suggests the stock may be stretched in the short term.
The 52-week high near $7.35 stands as the most important nearby resistance zone, and it sits below the $8.00 objective. A sustained advance toward the target would first need to clear that prior high and then break into territory the stock has not traded in for over a year. On the downside, the 50-day and 200-day moving averages, both near $3.30, form a key support band that has underpinned the recent recovery from the 52-week low near $2.07. The stock's steep single-day gain of about 25% in early October reflects the kind of low-liquidity, sentiment-driven moves that can reverse quickly.
A single analyst target of this kind is generally framed around a roughly twelve-month outlook, though the exact horizon is not disclosed in public summaries. Investors should watch the next quarterly report, estimated for November 12, 2026, for updates on QUELIMMUNE customer additions and revenue, the pace of NEUTRALIZE-AKI enrollment, and any commentary on cash runway and potential financing. Reimbursement developments, including the newly available ICD-10-PCS billing codes for SCD therapy, and any FDA milestones for the adult indication will also be relevant to whether the valuation case behind $8.00 strengthens or weakens.
For traders who prefer a data-driven approach, Tickeron's AI Daily Buy/Sell Signals offer a way to monitor opportunities across thousands of stocks and ETFs. The system uses artificial intelligence to continuously analyze changing market conditions, technical behavior, and AI-driven patterns, generating Buy, Sell, or Hold signals designed to help users spot shifting trends more efficiently. Rather than replacing independent research, it can serve as a screening and monitoring layer for active traders and investors tracking names like ICU. Explore the platform to see how its signals can complement your own analysis.
The $8.00 objective for SeaStar Medical is best understood as a single named analyst's price target rather than a broad consensus, and it implies a gain of roughly 70% from recent levels near $4.69. The case for reaching it rests on rapid revenue growth, high-margin device economics, expanding pediatric adoption, and the larger adult pipeline opportunity. The case against it centers on persistent losses, a limited cash position, heavy dilution, and execution risk in both the commercial launch and the pivotal adult trial. With the 52-week high near $7.35 acting as a meaningful hurdle just below the target, investors should focus on quarterly results, trial enrollment, and financing decisions before drawing conclusions. No outcome is guaranteed, and the target represents a research viewpoint, not a forecast of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ICU has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICU jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To ICU | 1D Price Change % | ||
|---|---|---|---|---|
| ICU | 100% | +3.93% | ||
| CANF - ICU | 93% Closely correlated | -0.02% | ||
| APVO - ICU | 85% Closely correlated | -0.93% | ||
| GNPX - ICU | 82% Closely correlated | -3.76% | ||
| TNXP - ICU | 77% Closely correlated | -6.06% | ||
| LONA - ICU | 62% Loosely correlated | +7.59% | ||
More | ||||